Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

262.90
-2.8900-1.09%
Pre-market: 260.60-2.3000-0.87%04:04 EDT
Volume:3.31M
Turnover:868.11M
Market Cap:464.65B
PE:74.27
High:265.00
Open:264.60
Low:260.31
Close:265.79
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.70
T/O Rate:0.19%
Dividend:6.83
Dividend Rate:2.60%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-78.29
PE(LYR):111.40

Loading ...

AbbVie Seeks EMA Approval for Skyrizi Subcutaneous Induction in Crohn’s Disease

Reuters
·
2 hours ago

Abbvie Submits Regulatory Application to Ema for Skyrizi® (Risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

THOMSON REUTERS
·
2 hours ago

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
11 hours ago

Gubra Earns USD 50 Million Milestone as AbbVie Starts Phase 2 Trial of Obesity Drug ABBV-295

Reuters
·
Yesterday

Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes

Reuters
·
Yesterday

China's Shandong Xinhua Profit Drops on Domestic, International Competition

Reuters
·
Aug 25

China's Innovent Biologics H1 Revenue, Profit Rise on Strong Product Sales

Reuters
·
Aug 25

Austar Lifesciences H1 Profit Drops on Higher R&D Spending

Reuters
·
Aug 25

WuXi Biologics H1 Net Profit up on Margin Expansion

Reuters
·
Aug 25

Stick with Value Stocks Until Everyone Starts Talking About Them - and as of Now They're Still Under the Radar, This Wall Street Firm Says

Dow Jones
·
Aug 25

Molecular Partners H1 Net Loss Narrows on Lower R&D Expenses

Reuters
·
Aug 25

Oruka Therapeutics Names Todd Edwards Chief Commercial Officer

Reuters
·
Aug 25

Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?

Simply Wall St.
·
Aug 25

ANI Pharma Appoints Henry Gosebruch to Board of Directors

Reuters
·
Aug 24

Johnson & Johnson, AbbVie, Chevron, Energy Transfer, Home Depot Shaken

TIPRANKS
·
Aug 22

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 22

AbbVie Expands Aesthetics Pipeline With New Phase 2 Forehead Lines Study

TIPRANKS
·
Aug 22

AbbVie Targets Pediatric Alopecia With New Phase 3 Trial: What Investors Should Watch

TIPRANKS
·
Aug 22

AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now

TIPRANKS
·
Aug 22

AbbVie Targets Next-Gen BOTOX Combo With New Glabellar Lines Study

TIPRANKS
·
Aug 21